What is APGE (APGE) stock price today?

APGE (APGE) is currently trading at $134.19, up 0.06% today.

What is APGE P/E ratio?

APGE's P/E ratio is -16.89. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is APGE return on equity (ROE)?

APGE's return on equity (ROE) is -28.47%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is APGE's market cap?

APGE has a market capitalization of $8.30B.

NASDAQ · Biotechnology

APGE (APGE) Stock

$134.19 +0.06% NASDAQ: APGE Healthcare

Valuation

Metric	Value
Price	$134.19
Market Cap	$8.30B
P/E Ratio	-16.89
P/B Ratio	5.20
P/S Ratio	0.00
EPS (TTM)	$0.00
52-Week High	$134.34
52-Week Low	$34.34
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-28.47%
ROA	-19.00%
ROCE	-31.64%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.01
Current Ratio	26.46

Annual Financials (USD)

Metric	2022	2023	2024	2025
Revenue	$0	$0	$0	$0
Operating Profit	$-31.0M	$-93.0M	$-217.0M	$-286.0M
Net Profit	$-40.0M	$-84.0M	$-182.0M	$-256.0M
EPS	$-0.79	$-1.66	$-3.30	$-4.22
Op Margin	—	—	—	—

Balance Sheet (USD)

Metric	2022	2023	2024	2025
Total Assets	$152.0M	$401.0M	$754.0M	$937.0M
Total Liabilities	$10.0M	$21.0M	$37.0M	$33.0M
Cash	$152.0M	$118.0M	$142.0M	$132.0M
Borrowings	$0	$2.0M	$12.0M	$9.0M

Latest News

What This Apogee Insider Move Might Mean After a 247% Stock Run Motley Fool · Jul 12, 2026 AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty Motley Fool · Jul 12, 2026 Apogee Therapeutics (APGE) Jumps Into Focus, Is The Stock Fully Valued? Simply Wall St. · Jul 10, 2026 Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says MT Newswires · Jul 8, 2026 Oruka Therapeutics H2 ORKA-001 Data Could Further De-Risk Lead Program, UBS Says MT Newswires · Jul 1, 2026

Cash Flow (USD)

Metric	2022	2023	2024	2025
Operating Cash Flow	$-16.0M	$-75.0M	$-171.0M	$-227.0M
Investing Cash Flow	$0	$-274.0M	$-302.0M	$-185.0M
Financing Cash Flow	$0	$0	$2.0M	$0
Net Cash Flow	$152.0M	$-33.0M	$23.0M	$-11.0M
Free Cash Flow	$-16.0M	$-75.0M	$-172.0M	$-233.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	-18.34
FCF Yield	-4.33%
Quick Ratio	32.59
Interest Coverage	—
Return 1Y	243.13%
Return 3Y	557.84%
Return 5Y	—

Ownership

Insiders Held2.37%

Institutions Held110.00%

Institutions Float Held112.66%

Institutional Holder	Shares	Report Date
T. Rowe Price Investment Management, Inc.	10,300,984	2026-03-31
FMR, LLC	9,262,291	2026-03-31
Venrock Adviser, LLC	8,493,321	2026-03-31
Wellington Management Group, LLP	4,375,703	2026-03-31
Blackrock Inc.	4,085,651	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPGAscentage Pharma Group International	$20.18	+4.89%	-9.87	$1.88B	0.00%
CELC	$92.49	+5.44%	-91.68	$4.51B	0.00%
CGON	$72.17	-1.84%	-26.72	$6.37B	0.00%
CNTACentessa Pharmaceuticals plc	$40.50	+0.00%	-22.75	$6.27B	0.00%
IRON	$73.86	-1.01%	-9.08	$2.82B	0.00%

About APGE

APGE is led by CEO Michael Thomas Henderson, employs 261 people, headquartered in Waltham, US, publicly traded since 2023.

APGE stock trades at $134.19 with a market capitalization of $8.30B. The stock is valued at a price-to-earnings (P/E) ratio of -16.89, price-to-book of 5.20, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $34.34 and $134.34, and currently trades at its 52-week high.

On profitability, APGE generates a return on equity (ROE) of -28.47%, return on capital employed of -31.64%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides